Difference between revisions of "Dostarlimab (Jemperli)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *4/22/2021: Granted accelerated approval for adult patients with [[Biomarkers#dMMR|mismatch repair deficient (dMMR)]] recurrent or advanced [[endometrial cancer]], as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen. | + | *4/22/2021: Granted accelerated approval for adult patients with [[Biomarkers#dMMR|mismatch repair deficient (dMMR)]] recurrent or advanced [[endometrial cancer]], as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen. ''(Based on GARNET)'' |
==Also known as== | ==Also known as== | ||
Revision as of 21:36, 29 April 2021
General information
Class/mechanism: PD-1 receptor antibody.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 4/22/2021: Granted accelerated approval for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen. (Based on GARNET)
Also known as
- Code name: TSR-042
- Generic name: dostarlimab-gxly
- Brand name: Jemperli